Oxford Biomedica Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Oxford Biomedica's earnings have been declining at an average annual rate of -62.7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 9.6% per year.
Wichtige Informationen
-62.7%
Wachstumsrate der Gewinne
-57.9%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 17.0% |
| Wachstumsrate der Einnahmen | 9.6% |
| Eigenkapitalrendite | -235.7% |
| Netto-Marge | -146.0% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Oxford Biomedica Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 97 | -142 | 25 | 81 |
| 31 Mar 24 | 93 | -150 | 25 | 92 |
| 31 Dec 23 | 90 | -157 | 25 | 103 |
| 30 Sep 23 | 104 | -110 | 25 | 110 |
| 30 Jun 23 | 119 | -62 | 25 | 117 |
| 31 Mar 23 | 130 | -50 | 24 | 106 |
| 31 Dec 22 | 140 | -39 | 23 | 95 |
| 30 Sep 22 | 133 | -32 | 21 | 82 |
| 30 Jun 22 | 126 | -25 | 19 | 69 |
| 31 Mar 22 | 134 | -3 | 17 | 58 |
| 31 Dec 21 | 143 | 19 | 14 | 47 |
| 30 Sep 21 | 139 | 19 | 13 | 41 |
| 30 Jun 21 | 135 | 19 | 13 | 34 |
| 31 Mar 21 | 111 | 6 | 12 | 37 |
| 31 Dec 20 | 88 | -6 | 11 | 40 |
| 30 Sep 20 | 77 | -9 | 12 | 39 |
| 30 Jun 20 | 66 | -13 | 13 | 38 |
| 31 Mar 20 | 65 | -14 | 12 | 34 |
| 31 Dec 19 | 64 | -16 | 12 | 30 |
| 30 Sep 19 | 64 | -12 | 10 | 26 |
| 30 Jun 19 | 64 | -8 | 9 | 22 |
| 31 Mar 19 | 65 | 0 | 8 | 20 |
| 31 Dec 18 | 67 | 8 | 7 | 19 |
| 30 Sep 18 | 62 | 4 | 7 | 22 |
| 30 Jun 18 | 57 | 0 | 7 | 25 |
| 31 Mar 18 | 47 | -5 | 7 | 23 |
| 31 Dec 17 | 38 | -9 | 7 | 22 |
| 30 Sep 17 | 34 | -10 | 6 | 22 |
| 30 Jun 17 | 31 | -11 | 5 | 22 |
| 31 Mar 17 | 29 | -14 | 6 | 23 |
| 31 Dec 16 | 28 | -17 | 6 | 24 |
| 30 Sep 16 | 26 | -16 | 7 | 24 |
| 30 Jun 16 | 24 | -16 | 8 | 24 |
| 31 Mar 16 | 20 | -15 | 7 | 22 |
| 31 Dec 15 | 16 | -13 | 7 | 20 |
| 30 Sep 15 | 15 | -12 | 6 | 20 |
| 30 Jun 15 | 13 | -10 | 5 | 19 |
| 31 Mar 15 | 13 | -9 | 4 | 18 |
| 31 Dec 14 | 14 | -9 | 4 | 17 |
| 30 Sep 14 | 11 | -9 | 4 | 15 |
| 30 Jun 14 | 8 | -10 | 3 | 14 |
| 31 Mar 14 | 7 | -11 | 3 | 14 |
| 31 Dec 13 | 5 | -11 | 3 | 14 |
Qualität der Erträge: OXBD.F is currently unprofitable.
Wachsende Gewinnspanne: OXBD.F is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: OXBD.F is unprofitable, and losses have increased over the past 5 years at a rate of 62.7% per year.
Beschleunigtes Wachstum: Unable to compare OXBD.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: OXBD.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: OXBD.F has a negative Return on Equity (-235.75%), as it is currently unprofitable.